Objective: In 2011, 15.8% of eligible patients in the United States were vaccinated against herpes zoster (HZ). To increase the usage of the HZ vaccine by studying physicians' knowledge, attitudes, practices, and perceived obstacles after interventions to overcome barriers. Methods: General internal medicine physicians were surveyed with a cross-sectional internet survey from October to December 2011 before interventions to increase the use of the HZ vaccine and 1 year later. Interventions included education, increasing availability at the medical center pharmacy, and electronic medical record reminders. Outcome measures included changes in knowledge, attitudes, and practices, and perceived barriers. McNemar chi-square tests were used to compare the changes from the baseline survey for physicians who completed the followup survey. Results: Response rate for the baseline study was 33.5% (89/266) and for the follow-up was 29.8% (75/252). Fifty-five completed both surveys. There was a decrease from 57% at baseline to 40% at follow-up in the proportion of physicians who reported that less than 10% of their patients were vaccinated. They were more likely to know the HZ annual incidence (30% baseline; 70% follow-up; P=0.02), and report having educational information for physicians (7% baseline; 27% follow-up; P=0.003). The top helpful intervention was nursing administration of the vaccine. Average monthly HZ vaccine usage in the affiliated outpatient pharmacy increased in 10 months between surveys by 156% compared with the 3 months before the baseline survey. Conclusions: Interventions implemented during the study led to an increase in physicians' basic knowledge of the HZ vaccine and an increase in usage at the affiliated pharmacy.
T here are more than 1,000,000 cases of herpes zoster (HZ) in the United States annually. [1] [2] [3] The incidence of HZ has been rising in the United States since the 1990s. 2, [4] [5] [6] [7] One third of all people in the United States will get HZ with the highest incidence in people aged 50 to 70. 2, 5 The Shingles Prevention Study (SPS) demonstrated that a HZ vaccine reduces the burden of illness by 61%, the incidence of postherpetic neuralgia by 66.5%, and incidence of zoster by 51.3%. 8 As a result, the US Food and Drug Administration (FDA) and Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention approved the Zostavax vaccine (Merck & Co Inc., Whitehouse Station, NJ) for the prevention of HZ in 2006 for immunocompetent patients aged 60 and above. 9 The FDA extended the approval to patients aged 50 to 59 in March 2011. 10 Postlicensure studies have continued to demonstrate the efficacy and safety of the HZ vaccine. [11] [12] [13] [14] [15] [16] Despite this evidence, the uptake of zoster vaccination among eligible patients has been significantly less than other standard adult vaccines since licensure. 1, [17] [18] [19] [20] Centers for Disease Control and Prevention estimates show that only 15.8% eligible patients received the vaccine in 2011, up from 14.4% in 2010, 10% in 2009, and 6.7% in 2008. 20, 21 The 2011 rates were even lower in African Americans (7.9%) and Hispanics (8.0%).
Hurley et al. 18 identified the top barriers for physicians as the perceived cost to patients, reimbursement difficulties, and the upfront cost of stocking the vaccine. Evidence shows that a lack of strong physician recommendation continued to be a major barrier to patient adherence with national guidelines. 18, 19 The previously published baseline survey results show that only 66% of general internal medicine (GIM) physicians responded that the HZ vaccination was an important clinical priority, and 48% reported that less than 10% of their patients received the HZ vaccine. 22 The top barrier to vaccination was cost to patients, and the lack of awareness of national recommendations varied by provider setting.
The purpose of the study was to use a follow-up survey to measure whether institution-wide interventions would increase the prescriptions of the HZ vaccine by GIM physicians at a major urban academic medical center 1 year after the baseline survey. The surveys were based on the work of Cabana et al., which described that to overcome barriers to physician adherence to evidence-based practice, there must first be a change in knowledge and then attitudes to finally affect behavior. 23 Furthermore, we aimed to determine whether changes in use of the HZ vaccine depend on exposure to interventions by 4 different practice sites affiliated with the medical center. Interventions included education for GIM physicians through presentations and other conferences, education for patients advertised on plasma screens in the medical center, option for administration by nurse at pharmacy with a prescription at the outpatient pharmacy, and electronic medical record (EMR) health maintenance reminders and alerts.
MATERIALS AND METHODS
From October 6 to December 12, 2011, SurveyMonkey (SurveyMonkey, LLC, Palo Alto, CA) Institutional Review Board-approved surveys were sent to 266 valid faculty email addresses of all members of the Division of General Internal Medicine (DGIM) in the Department of Medicine of New York University Langone Medical Center (NYULMC). The same survey was sent to 252 valid DGIM faculty email addresses from October 1 to December 21, 2012 for a 1-year follow-up. The follow-up survey period was extended because of disruptions from Hurricane Sandy at the Medical Center between October 29 and November 26, 2012. Faculty members are required to have NYULMC email addresses, therefore all eligible physicians in the four practice settings described below were reached by email. Ten email reminders were sent to nonresponders during the survey periods. At the end of the survey period, correct answers to the knowledge-based questions were emailed. There were no exclusion criteria.
Surveyed physicians practice in different outpatient settings included the Faculty Group Practice (FGP) at NYULMC, voluntary private practices affiliated with NYULMC (Vol), outpatient clinics of the public Health and Hospitals Corporation at Bellevue Hospital and Gouverneur Healthcare Services (BG), and the Primary Care Clinic at the Manhattan Veterans Affairs (VA). The FGP doctors are employees of NYULMC with a high percentage of insured patients; Vol physicians have private offices located throughout the area with access to the NYU Pharmacy; BG is a safety net hospital system without the HZ vaccine on formulary at its pharmacy; and the VA hospital serves a large population of veterans with a well-developed EMR, and the HZ vaccine provided through its pharmacy.
The survey assessed the baseline knowledge, attitudes, practices, and perceived barriers regarding HZ and the vaccine against it. The survey used close-ended items to record physician background characteristics. Multiple choice questions and simple case vignettes were used to assess knowledge of the nature of HZ, vaccination safety, efficacy, guidelines, and procedures for obtaining the vaccine. Likert-type attitude items were included to further understand the priority of vaccination against HZ and perceived barriers to ordering and administering the vaccine. Close-and open-ended questions were included to measure current practices with the vaccine and experiences prescribing the vaccine to patients. Doses of the HZ vaccine administered and number of prescribers at the medical center outpatient pharmacy used by the physicians were monitored. All patients have access to this pharmacy, however, BG and VA have separate outpatient pharmacies not monitored during the study.
All analyses were conducted with SAS 9.3 (SAS Institute Inc., Cary, NC). For respondents to both the baseline and follow-up surveys, changes in responses from baseline to the follow-up were evaluated using statistical tests for paired data. For the survey questions with qualitative responses, McNemar chi-square tests were used to compare whether the distributions of the responses to each question were significantly different at two-sided alpha level of 0.05. For those questions with quantitative responses, Wilcoxon signed-rank nonparametric tests were used to compare the distributions of responses. In these analyses, no adjustments for multiple questions were used.
For the follow-up survey, we compared the distributions of the responses of physicians from the four practice sites (FGP, Vol, BG, and VA). Fisher's exact tests were used to investigate whether the distributions of the responses to each question were significantly different at two-sided alpha level of 0.05 among the four groups. For those questions with quantitative responses, Kruskal-Wallis nonparametric analysis of variance methods were used to compare the mean responses among the four groups. For those questions with statistically significant differences among groups of respondents, all pairwise comparisons between groups were tested with a Bonferroni correction to adjust for the multiple comparisons (P value for statistical significance #0.0083). No adjustment for multiple questions was applied.
RESULTS

Respondent Characteristics
The total response rate for the baseline survey was 33.5% (89/ 266) and for the follow-up survey 29.8% (75/252); however, only 64 identified a primary working site to be included in the analysis. Table 1 summarizes the baseline characteristics for the 55 physicians who completed both surveys. There were minimal changes from the baseline survey to the follow-up survey regarding the numbers of outpatients they saw annually, percentages of their patients who filled prescriptions at the NYU Pharmacy, who were over 60 years of age, and number of HZ vaccine prescriptions last year (all values of P$0.090). There was no statistical difference among the sites in either survey regarding the percentage of physicians who completed fellowship, and the majority (71% at preliminary and 74% in the follow-up survey) did not complete fellowship.
There was a statistical difference in the estimated percentage of patients immunocompromised, and therefore not eligible for vaccinating patients among the four practice settings in both surveys, with a trend of BG physicians estimated to have the most immunocompromised and Vol estimated to have the least (P=0.007 and P=0.002 for the preliminary and follow-up surveys, respectively). These trends were expected before conducting the survey. However, the differences among the groups did not change between the surveys (P=0.1).
Physician Knowledge, Attitudes, and Practices
Regarding the HZ Vaccine Before and After Interventions Table 2 describes the knowledge, attitudes, and practices among the 55 physicians who responded to both surveys. Physicians tended to answer more knowledge-based questions correctly in the follow-up than the baseline (Table 2) . Notably, the proportion of physicians who answered the question regarding shingles incidence correctly (approximately 1,000,000 cases of shingles per year in the United States) increased from 30% (6/20) to 70% (14/20) (P=0.02).
Among the top reported barriers to HZ vaccination, there was an 8% decrease in the number of physicians who reported cost to Z. P. Elkin et al.
Eye & Contact Lens Volume 40, Number 4, July 2014 patients as a barrier to vaccination (81% [30/37] at baseline to 73% [27/37] at follow-up), and a 6% decrease in the physicians who agreed that HZ vaccination rates were lower than they should be because physicians are not aware of recommendations (76% [28/37] at baseline to 70% [26/37] at follow-up) ( Table 2 ). The proportion of physicians who responded that they have a lot more to focus on with patients to recommend the HZ vaccine decreased (51% [19/37] at baseline to 32% (12/37) at follow-up; P=0.06).
This change was largely driven by fewer BG physicians agreeing with this barrier (67% [12/18] at baseline to 39% [7/18] at follow-up; P=0.06).
The proportion of physicians reporting that less than 10% of their patients older than 60 years received HZ vaccines decreased from 57% (17/30) at baseline to 40% (12/30) at follow-up. At the same time, the proportions of physicians reporting that more than 75% of their patients received pneumococcal vaccine was 57% Eye & Contact Lens Volume 40, Number 4, July 2014 National Recommendations for Zoster Vaccination (21/37) for both baseline and follow-up surveys. Those reporting that more than 75% received influenza vaccines were 55% (21/37) at baseline and 50% (19/38) at follow-up. During the study period, monthly medical center pharmacy HZ vaccine prescriptions and number of physicians prescribing the HZ vaccine increased after implementation of key interventions (Fig. 1) . For example, there was a 136% increase in HZ prescriptions in the 3 months before the baseline survey (average, 47; range, 33-59) compared with the 3 months before the follow-up survey (average, 111; range, 99-124), and a 156% increase in the 3 months before the baseline survey compared with the 10 months between surveys (average, 120; range, 93-159).
Physician Responses to Interventions
The top "helpful" interventions reported among the 55 physicians who answered both surveys were administration of vaccine by a nurse after a prescription by physicians, making physicians aware of ACIP-recommended immunization schedules, nurseinitiated prompting about vaccination, reminders in patient charts, and having a pharmacy administer the vaccine with or without a physician prescription (Table 3) . Particularly, VA physicians at follow-up (90% [9/10]) were more likely to answer that having a pharmacy administer the HZ vaccine after a prescription by a physician would be helpful than at the baseline (P=0.06).
Physicians at the follow-up survey were more likely to respond that they already had nurses administer the vaccine after a prescription by the physician, nurse-initiated prompting about vaccination with the patients, multipronged interventions, and education for physicians about the severity of HZ in place (Table 3) . Among the 55 physicians who answered both surveys, 27% (15/55) of physicians at follow-up were significantly more likely to report having education for physicians about the severity of HZ compared with 7% (4/55) at baseline (P=0.003).
Physician Knowledge, Attitudes, and Practices Regarding the HZ by Provider Site
The 64 responses to the follow-up survey were also compared across the four practice sites. Responses to knowledge-based questions varied by question type and provider setting in the follow-up survey ( Table 4 ). Faculty Group Practice physicians were more likely to know that there are 1,000,000 cases of shingles per year in the United States than BG (80% and 23%, respectively; P=0.008). Physicians at all provider sites agreed that ACIP recommendations were important for HZ vaccination practices; however, over 60% of physicians at all sites agreed that vaccination rates were low because physicians were not aware of these recommendations. Additionally, both BG (86%) and Vol (100%) reported that the HZ vaccine was too costly more often than VA (14%) (both pairwise, P,0.001). Furthermore, BG (71%) was more likely to report that ordering and administering HZ vaccine was too complicated compared with FGP (10%) (P=0.002). Regarding current vaccination practices, BG (84%) was more likely to report less than 10% of patients receiving the HZ vaccine than FGP (0%) and VA (20%) (both pairwise, P,0.001).
DISCUSSION
The HZ vaccine continues to be shown to be safe and efficacious since approval. A postlicensure study found efficacy for preventing HZ in persons 50 to 59 years old to be 69.8%, 11 and a Cochrane Review of 3 randomized controlled studies related to HZ vaccination efficacy found a risk ratio of having HZ to be 0.49 in all vaccinated patients versus unvaccinated patients. 13 Furthermore, the 4-year follow-up to the SPS showed continued efficacy, but reductions in the burden of illness decreased from 61% to 50.1%. 14 Therefore, improving vaccination rates among eligible patients is an important clinical priority.
We hypothesized that by introducing interventions to influence GIM physicians' knowledge and attitudes related to the HZ vaccine, there would be a change in provider practices to increase the use of the HZ vaccine among eligible patients. Overall, average monthly HZ vaccine usage in the NYU pharmacy increased in the 10 months between surveys by 156% compared with the 3 months before the baseline survey before interventions. Among physicians that participated in both the baseline and follow-up surveys, they were statistically more likely to know that there are more than 1,000,000 cases of HZ annually in the United States (30% baseline; 70% follow-up; P=0.02), and more likely to report having education for physicians about the severity of HZ (7% baseline; 27% follow-up; P=0.003). Furthermore, consistent with Cabana et al., 23 worse prioritization of the HZ vaccine suggested worse adherence to national recommendations. Eighty-three percent (30/36) at baseline but only 69% (25/36) on follow-up responded that HZ vaccination was an important clinical priority. Comparatively, physicians indicated that their clinical priorities regarding the importance of pneumococcal and influenza vaccination were above 90% for both surveys. Correspondingly, it was reported that less than 10% of their patients received the HZ vaccines by 57% (17/30) physicians at baseline compared with 40% (12/30) on follow-up. Greater than 50% of respondents reported that over 75% of their patients received the pneumococcal and influenza vaccines during both surveys. However, there was no statistical difference between baseline and follow-up vaccination proportions among the 55 physicians who answered both surveys.
As in the baseline survey, significant differences in physician attitudes and practices remained among the 4 different provider sites in the follow-up survey. 22 BG and Vol were more likely to report cost as a barrier to vaccination, and BG, without the vaccine on formulary, expressed greater difficulties in ordering and administering the vaccine. As a result, BG physicians were more likely to respond that less than 10% of their patients received the HZ vaccine. There are several reasons why we may not have seen major changes in many questions. First, the survey responders were potentially less likely to benefit from the interventions than the nonresponders. The EMR reminders were available only on EPIC, which was only used by 13% of responders on the baseline and follow-up survey. The NYU pharmacy showed a large increase in HZ prescriptions and physicians writing prescriptions after the interventions, but the percent of patients who used that pharmacy per physician was low in both baseline and follow-up surveys. This intervention would be more likely to affect the FGP and Vol, which used the NYU pharmacy more than BG and VA. However, the increase in educational programs in physician practices and usage at pharmacy suggest that interventions may have had an impact not detected by survey.
Second, the lack of adherence to guidelines is undermined by system and environmental factors. 23 For example, patients on Medicaid or uninsured have overall lower HZ coverage and difficulty accessing adult vaccines, despite being covered by Medicaid. 1, 24 Forty-five percent of responders in the baseline survey and 52% in the follow-up survey were BG physicians where the HZ vaccine is not on formulary. Changes in attitudes and practices are unlikely to be seen in the survey results when nearly half of the sample size still cannot offer their patients the HZ vaccine at their practice site.
Third, one of the top helpful interventions identified in the baseline survey was nurse-initiated prompting about vaccination with the patients, which was not included in the interventions. The interventions used were predefined at the start of the study based on successful interventions in the literature, particularly for EMR reminders. Chaudhry et al. 25 evaluated clinical decision support software as part of EMR at the Mayo Clinic and found an increase in vaccine utilization of 43% and 54% at 2 clinics. However, there is evidence the physician reminders are less effective than patient reminders regarding increasing influenza vaccination rates, 26 and nurse-initiated reminders with EMR reminders are more effective than EMR reminders alone. 27 Therefore, additional practice interventions like nurse-initiated prompting or patient reminder and recall systems could potentially show a greater change in physician practices. [28] [29] [30] A continued expanded role for nurses in promoting vaccinations and other recommended preventive care should be considered.
Lastly, diffusion of a novel vaccine into standard clinical practice may take more time than the 1-year follow-up to assess change. For example, in 2011, only 62.3% of eligible patients in the United States received the pneumococcal vaccine. 21 Interventions to increase the use of that vaccine started in 1981 with Medicare covering it, but by 1989, only 14.1% of eligible adults 65 years and older were vaccinated. 31 The HZ vaccine was only approved for immunocompetent patients 60 years and older in 2006. Healthcare system-wide changes were only beginning during this study. For example, New York state began to allow certified pharmacists to administer the HZ vaccine with a prescription in October 2012, and Merck began a marketing campaign about shingles that year as well. More time may be needed to measure changes in patient and provider behaviors.
This study has additional limitations. The response rate was 29.8% for the baseline survey and only 25.4% for the follow-up. The lower response rate during the follow-up may be in part due to Hurricane Sandy, which closed much of the medical center, NYU pharmacy, and affected many voluntary practices during the follow-up survey. In addition, the study relied on self-reported practices, which may not reflect actual practices that could be obtained from administrative or medical records. Finally, these results present the responses of physicians at one large, diverse major urban academic medical center, which may not be generalizable to other settings.
From this study, we were able to add to the growing literature that there continues to be underutilization of the HZ vaccine, despite ongoing support for its safety and efficacy. Overall, the GIM physicians know the severity of HZ and have improved knowledge related to the epidemiology of the disease. They do not, however, universally know about the ACIP recommendations, and that combined with the barriers of cost and difficulties administering the vaccine limit their positive attitudes toward the vaccine. Simple interventions such as having a nurse present in the pharmacy to administer the vaccine greatly increased usage. Additional practice-specific interventions like nurse-initiated prompting may further increase the use of the HZ vaccine and strengthen physician recommendations.
